DENDRIMERS AND POLYMER DRUGS CONJUGATE MARKET ANALYSIS

Dendrimers and Polymer Drugs Conjugate Market, by Dendrimer Type (Poly – etherhydroxyethyl amine (PEHAM), Poly - esterhydroxyethyl amine (PEA), Poly - amido amine (PAMAM), Poly – L – lysine, Poly – propylene imine, and Others), By Application (Oncology, Infectious Diseases, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Sep 2024
Code : CMI2628
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Dendrimers and Polymer Drugs Conjugate Market Regional Analysis

North America is expected to be the dominant region in the global dendrimers and polymer drugs conjugate market. Presence of manufacturers like Eli Lilly & Co., Dade Behring and Nektar Therapeutics, potential customer base, and frequent research and development activities by key players is expected to drive North America dendrimers and polymer drugs conjugate market growth. For instance, in November 2016, Nektar Therapeutics commenced its investigational study on NKTR-102. The drug is being studied for the treatment of metastatic breast cancer. It contains irinotecan (dendrimer)/ Topoisomerase I inhibitor, and is currently in the third phase of clinical trial. Such key research and development activities are expected to drive the global dendrimers and polymer drugs conjugate market growth.